Skip to main content
  1. Home
    /
  2. IPO
    /
  3. Amanta Healthcare IPO
Amanta Healthcare IPO
81.96xsubscribed

Amanta Healthcare IPO

Pharmaceuticals & Drugs
listed
₹14,280Min. investment

Amanta Healthcare Limited IPO Details

SectorPharmaceuticals & Drugs
Price range₹120 – ₹126
IPO type
Regular
Lot size119 shares
Issue size₹126Cr
Red Herring Prospectus
Read
Market cap
₹489.25CrLower than sector avg
RevenueApr 2024 - Mar 2025
₹274.71CrLower than sector avg
Growth rate3Y CAGR
1.97%

Amanta Healthcare IPO Subscription Status

Date
QIB
NII
Retail
Total
01-Sep-25
0.03 times (X)
5.82 times (X)
6.81 times (X)
4.67 times (X)
02-Sep-25
0.29X
36.22X
23.51X
19.72X
03-Sep-25
30.08X
207.3X
53.92X
81.96X

As on 01-Sep-25, 5:30 PM

Amanta Healthcare IPO Timeline

  1. Pre-apply
    29 Aug 2025
  2. Bid start
    1 Sep 2025
  3. Bid end
    3 Sep 2025
  4. Allotment
    4 Sep 2025
  5. Release of funds
    8 Sep 2025
  6. Demat transfer
    8 Sep 2025
  7. Listing
    9 Sep 2025

About Amanta Healthcare Limited

Incorporated in 1994, Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products, including parenteral products, packed in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technology. The company manufactures large-volume parenterals (LVPs) and small-volume parenterals (SVPs) across 6 therapeutic segments, along with medical devices.
The company operates through 3 strategic business units: national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. The company markets over 45 products under its own brands in the Indian market through a network of over 320 distributors and stockists. The international sales contributed 32.68% of total revenue in FY25 compared to 29.31% in FY24.
It operates a manufacturing facility spread over 66,852 sq m in Gujarat, India. The facility includes four large-volume parenterals (LVP) manufacturing lines and three operational small-volume Parenterals (SVP) manufacturing lines. The company offers a comprehensive range of products, including fluid therapy (IV fluid), formulations, diluents, ophthalmic solutions, respiratory care and irrigation solutions in the therapeutic segment, plus products like irrigation, first-aid solutions, and eye lubricants in the medical device segment. As of 22 Aug 2025, the company has a portfolio of 47 products registered across 120 international jurisdictions.
As of March 31, 2025, the company achieved overall capacity utilisation of 96%, with LVP at 91%, SVP at 99%, and SteriPort at 91% utilisation rates. Total installed capacity stands at 33.19 crore units with actual production of 31.83 crore units.
Global health expenditure was US$9.8T in 2022, approximately 9.9% of world GDP. India’s current health expenditure (CHE) is only 3.3% of GDP, well below developed peers, suggesting a long runway as policy focus post-COVID sustains spending. Per-capita CHE in India is just US$273, again highlighting headroom. Health’s share in India’s private final consumption expenditure has risen steadily to 5.2% in FY24. The National Health Policy targets lifting government health outlay to 2.5% of GDP; pharma accounts for a relatively high share of CHE in India (21% in 2020), indicating structural demand for cost-effective therapies and essential hospital consumables.
Amanta focuses on sterile liquids (LVPs/SVPs) across fluid therapy, diluents, ophthalmic, respiratory and irrigation, directly exposed to rising hospitalisations and procedure volumes as health spending climbs from a low base. Two-port IV fluids enjoy materially higher ceiling prices than single-port, e.g., 500 ml glucose 5% at ₹82.27 vs ₹37.98. The company sells two-port under SteriPort, allowing it to skew to higher-realisation SKUs while remaining within price controls.
Now, Amanta Healthcare Ltd is launching its initial public offering (IPO), which is a complete fresh issue worth ₹126 crore. Its shares will be listed on the NSE and BSE.

Checklist

Quality analysis
Revenue growth
Company valuation
Earnings expansion
Risk analysis
Debt to Equity ratio
Promoter holdings
Shares pledged
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Strength and Weakness

Well-diversified product portfolio

The company offers products across 6 therapeutic segments - fluid therapy, formulations, diluents, ophthalmic, respiratory care and irrigation solutions with 47 products registered. The wide container offerings, ranging from 2 ml to 1000 ml, with closure systems such as nipple head, twist-off, leur-lock and screw types, further strengthen its diversified product base.

Strong manufacturing capabilities

The facility, spread over 66,852 sq. metres in Kheda, Gujarat, houses 4 LVP lines (2 ABFS and 2 ISBM) and 3 SVP lines (2 ABFS and 1 conventional). With the ability to manufacture sterile liquids from 2 ml to 1000 ml at a single location, it holds ISO and WHO-GMP certifications, ensuring quality compliance.

Wide sales and distribution network

The company has a domestic network of 320 distributors/stockists supported by a 96-member sales team, supplying to hospitals and nursing homes. International registrations across 120 jurisdictions strengthen its global reach.

Technology-enabled operations

The company employs advanced manufacturing technologies such as Form Fill Seal (FFS), producing ~8 bottles every 15 seconds with nitrogen purging, and Injection Stretch-Blow Moulding (ISBM) with automated terminal sterilisation at 109°C, ensuring sterile, high-quality output. On the commercial side, pharma cloud and sales force automation enable efficient demand planning, forecasting, cost control, and risk management.

Objectives of Amanta Healthcare Limited IPO

Funding of Capex
79.47%
The company will utilise ₹100.13 crore towards civil construction work of new manufacturing units.
General corporate purposes
20.60%
Part of the IPO proceeds will be used for general corporate purposes.

Compare

CompanyRevenue*3Y growthPATMarket capP/E ratioD/E ratio
This IPO₹274.71Cr1.97%₹10.5Cr₹489.25Cr33.962.02
This sector (avg.)₹1,331.47Cr0%₹193.4Cr₹10,914.84Cr60.870.43
₹52,578.44Cr---₹10,980.1Cr₹3,82,765.9Cr36.980.03
₹9,360Cr---₹2,191Cr₹1,60,635Cr64.600
₹11,516.09Cr---₹1,911.25Cr₹1,34,051.5Cr62.640.42

*Revenue for financial year 2024-25. Lower P/E and D/E ratios are generally preferred.

Amanta Healthcare IPO Contact Details

Company NameAmanta Healthcare Limited

How to apply for Amanta Healthcare IPO?

  1. Step 1

    Log in to your Upstox account to access IPO investments. Next, select the current IPO section.

  2. Step 2

    Specify IPO details. Enter the number of lots and the price you wish to apply for.

  3. Step 3

    Enter UPI ID. After entering your UPI ID, click submit. This will place your bid with the exchange.

  4. Step 4

    Mandate Notification. Your UPI app will receive a mandate notification to block funds.

  5. Step 5

    Approve Request. Your funds will be blocked once you approve the mandate request on your UPI.

Amanta Healthcare Limited IPO FAQs

Investors can apply for the Amanta Healthcare IPO through their Demat account via the stock exchange or through their broker.
The issue size of the Amanta Healthcare IPO is 126 Cr.
Pre-applying for an IPO allows you to submit your application before the official subscription period begins.
The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.
Amanta Healthcare IPO will be open between 2025-09-01 and 2025-09-03.
Amanta Healthcare IPO allotment date is 2025-09-08. For Amanta Healthcare IPO allotment status check, you can visit the website of the registrar of the IPO.
For Amanta Healthcare IPO, the IPO registrar is MUFG INTIME INDIA PRIVATE LIMITED. You can check Amanta Healthcare IPO allotment status on the website of the registrar.
The shares are proposed to be listed on the BSE and NSE.
The Amanta Healthcare IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.
The Amanta Healthcare IPO lot size is 119 and minimum order quantity is 119.
Amanta Healthcare IPO has set the price band for its IPO at 126 per equity share with a face value of 10.